fda glp-1 news november 2025 weight loss drugs are back in the FDA proposes a new GLP-1

Acute stress and large meals trigger GLP-1 in the brain to suppress appetite, preventing overeating

However, this decision should always be made in consultation with a healthcare provider and based on your complete cardiovascular risk profile, family history, and lipid levels

For diabetes management , the most important metric is blood glucose control

Importantly, the improved menstrual regularity seen in women with PCOS on semaglutide, where 80 percent of responsive patients normalized their cycles, suggests that the medication can be profoundly positive for reproductive and sexual health in the right population

Some patients develop injection site reactions, bruising, or discomfort